Albuterol nebulized in heliox in the initial ED treatment of pediatric asthma: a blinded, randomized controlled trial - 18/08/11
, Gail M. Stewart, DO b, Lilit Minasyan, MD b, Lance Brown, MD, MPH bAbstract |
Objective |
A prospective blinded, randomized controlled trial was undertaken to compare the initial response of albuterol nebulized in heliox or control in the treatment of moderately severe asthma in children presenting to a pediatric ED.
Methods |
Patients were randomized to receive heliox (n = 20) or control (n = 21). The primary outcome was to compare a modified dyspnea index score at 10 and 20 minutes after randomization. Secondary outcomes were to determine if heliox decreased admission rates or endotracheal intubation.
Results |
There was no statistically significant difference found at 10 or 20 minutes after randomization with heliox (P = .169 and P = .062, respectively). No statistical difference in admission rate was found, and no patients required endotracheal intubation in either group.
Conclusions |
Our results demonstrate that albuterol nebulized with heliox offered no clinical benefit over standard therapy in the initial treatment of moderately severe asthma in the ED.
Le texte complet de cet article est disponible en PDF.Plan
| ☆ | Departmental funds were the sole support for this project. |
Vol 24 - N° 1
P. 38-42 - janvier 2006 Retour au numéro
Article précédent
- Changes in access to primary care for Medicaid beneficiaries and the uninsured: the emergency department perspective
- Robert A. Lowe, K. John McConnell, Rongwei Fu, Cody C. Weathers, Jill Boyer-Quick, Annette L. Adams, Beverly Bauman
- Impact of helical computed tomography on the rate of negative appendicitis
- Tyler F. Vadeboncoeur, Robyn R. Heister, Cynthia A. Behling, David A. Guss
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?